Last updated: 2026-09-09 08:05:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Organogenesis Holdings Inc. (ORGO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.60, with a market capitalization of $220.03M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.54 to $7.08. This page covers its latest market performance, valuation, price trends and company information.
$220.03M | |
$1.60 | |
$310.90 | |
$1.54 | |
$1.60 | |
100.00 | |
807.68K | |
-- | |
$7.08 | |
$1.54 | |
-- | |
-- |
Organogenesis Holdings Inc. (ORGO) is trading at $1.60 in pre-market trading as of 2026-09-09 08:01:00, down 0.31% ($0.01) from the previous close of $1.60
Pre-market trading shows how investors are pricing ORGO before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Organogenesis Holdings Inc. (ORGO) moved from $1.74 to $1.60, representing a decline of 8.33% ($0.15).
The stock traded between $1.57 and $1.75 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 750.67 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.0%
ORGO is currently trading at $1.60, placing it 1.0% of the way from its 52-week low of $1.54 to its 52-week high of $7.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 854 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Organogenesis Holdings Inc. (ORGO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.